priors.science/reviews/tnf-alpha-inhibitors

TNF Alpha Inhibitors

The current evidence on 14 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

14claims tracked
90primary papers reviewed
6 Jul 2026latest evidence review
Weeklyre-scored against new papers
9 Established · 5 Likely · 0 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableTNF-alpha inhibitors reduce signs and symptoms of rheumatoid arthritis versus placeboRAEstablished97%6
StableTNF-alpha inhibitors combined with methotrexate are superior to methotrexate monotherapy in RARAEstablished95%6
StableTNF-alpha inhibitors increase the risk of serious infections including tuberculosis reactivationSafEstablished95%6
StableInfliximab and adalimumab induce remission in moderate-to-severe Crohn's diseaseIBDEstablished94%6
StableTNF-alpha inhibitors are effective in ankylosing spondylitis and axial spondyloarthritisSpaEstablished93%6
StableTNF-alpha inhibitor biosimilars are equivalent in efficacy and safety to reference biologicsBioEstablished91%6
StableTNF-alpha inhibitors inhibit radiographic joint damage progression in RARAEstablished91%6
StableTNF-alpha inhibitors achieve PASI 75 response in moderate-to-severe plaque psoriasisPsoEstablished90%6
StableTNF-alpha inhibitors are effective in psoriatic arthritisSpaEstablished88%6
StableTNF-alpha inhibitors are contraindicated in moderate-to-severe heart failureSafLikely84%6
StableTNF-alpha inhibitors maintain steroid-free remission in ulcerative colitisIBDLikely82%6
StableTNF-alpha inhibitors can trigger demyelinating disease and are contraindicated in multiple sclerosisSafLikely82%6
StableSerum drug level monitoring improves TNF-alpha inhibitor outcomes in inflammatory bowel diseaseBioLikely74%6
StableTNF-alpha inhibitors are associated with increased lymphoma riskSafLikely72%6
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic